Literature DB >> 31919473

Obeticholic acid for the treatment of NASH.

Jordan Hindson1.   

Abstract

Entities:  

Year:  2020        PMID： 31919473     DOI： 10.1038/s41575-020-0264-1

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  4 in total

1.  Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression.

Authors:  Nisreen Nimer; Ibrahim Choucair; Zeneng Wang; Ina Nemet; Lin Li; Janet Gukasyan; Taylor L Weeks; Naim Alkhouri; Nizar Zein; W H Wilson Tang; Michael A Fischbach; J Mark Brown; Hooman Allayee; Srinivasan Dasarathy; Valentin Gogonea; Stanley L Hazen
Journal:  Metabolism       Date:  2020-12-01       Impact factor: 8.694

Review 2.  Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.

Authors:  Hyunmi Kim; Da Som Lee; Tae Hyeon An; Hyun-Ju Park; Won Kon Kim; Kwang-Hee Bae; Kyoung-Jin Oh
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

3.  Increased Liquefactive Necrosis Formation After Transarterial Chemoembolization Combined with Molecular Targeted Agents Plus Immune Checkpoint Inhibitors for Hepatocellular Carcinoma.

Authors:  Yingliang Wang; Chen Zhou; Jiacheng Liu; Qin Shi; Songjiang Huang; Chongtu Yang; Tongqiang Li; Yang Chen; Bin Xiong
Journal:  Cancer Manag Res       Date:  2021-09-07       Impact factor: 3.989

Review 4.  New Drugs for Hepatic Fibrosis.

Authors:  Liang Shan; Fengling Wang; Dandan Zhai; Xiangyun Meng; Jianjun Liu; Xiongwen Lv
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.